Search: onr:"swepub:oai:DiVA.org:liu-168293" >
Health Care Costs o...
-
Hagström, HannesKarolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden
(author)
Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls
- Article/chapterEnglish2020
Publisher, publication year, extent ...
-
ELSEVIER SCIENCE INC,2020
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-168293
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-168293URI
-
https://doi.org/10.1016/j.cgh.2019.10.023DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:144241414URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies|Stockholm City Council; Bengt Ihre Foundation; County Council of Ostergotland, Sweden [Dnr RS 2017-407-2]
-
BACKGROUND & AIMS: Data on healthcare resource use and costs associated with nonalcoholic fatty liver disease (NAFLD) in clinical practice are lacking. We compared real-life healthcare costs of patients with NAFLD to matched controls. METHODS: We performed a retrospective study of 646 patients with biopsy-proven NAFLD in Sweden from 1971 through 2009. Each patient was matched for age, sex, and county of residence with 10 persons from the general population (controls). We retrieved all healthcare contacts through Dec 31, 2014 from national registers. Unit costs were assigned to arrive at a total healthcare cost (in USD [$]) per study subject. RESULTS: During a mean follow-up of 19.9 years, we recorded a mean of 0.27 hospitalizations per year for patients with NAFLD vs 0.16 for controls (P <.001). This corresponded to an incremental cost of $635 per year for patients with NAFLD. Patients with NAFLD had a higher mean use of outpatient care visits: 1.46 contacts per year compared with 0.86 per year in controls, corresponding to $255 in additional costs (P <.001). Total costs incurred by patients with stage 3-4 fibrosis were higher than by patients with fibrosis stage 0-2 (mean annual costs, $4397 vs $629). Cumulative costs were higher for all stages of fibrosis compared to controls. CONCLUSIONS: Healthcare costs are nearly twice as high in patients with NAFLD than in matched controls. This is mostly attributable to higher costs for hospitalizations, but also to more outpatient visits. Patients with advanced fibrosis had the highest costs.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Nasr, PatrikLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken(Swepub:liu)patna19
(author)
-
Ekstedt, MattiasLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken(Swepub:liu)matek92
(author)
-
Hammar, UlfKarolinska Inst, Sweden
(author)
-
Widman, LinneaKarolinska Institutet,Karolinska Inst, Sweden
(author)
-
Hultcrantz, RolfKarolinska Institutet,Karolinska Inst, Sweden
(author)
-
Kechagias, StergiosLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken(Swepub:liu)steke00
(author)
-
Henriksson, MartinLinköpings universitet,Avdelningen för samhälle och hälsa,Medicinska fakulteten(Swepub:liu)marhe38
(author)
-
Stål, PerKarolinska Institutet,Karolinska Institutet, Sweden
(author)
-
Karolinska InstitutetKarolinska Univ Hosp, Sweden; Karolinska Inst, Sweden
(creator_code:org_t)
Related titles
-
In:Clinical Gastroenterology and Hepatology: ELSEVIER SCIENCE INC18:7, s. 1592-+1542-35651542-7714
Internet link
Find in a library
To the university's database